24 weeks
Primary objective:~To assess the disease control of moderate to severe atopic dermatitis in patients aged 12 years and above treated with dupilumab therapy using Atopic Dermatitis Control Tool (ADCT) after 24 weeks of treatment.~Secondary objectives:~To figure the proportion of patients with reduction of ADCT score by 5 points after 4, 12, and 24 weeks of treatment.~To figure the proportion of patients with ADCT score less than 7 at weeks 4, 12, and 24.~Assess the effectiveness of dupilumab in moderate to severe atopic dermatitis (AD) patients, using the severity score as routine practice SCORing Atopic Dermatitis (SCORAD).~To describe comorbidities related to type 2 inflammation.~To characterize the safety profile of dupilumab in the local Gulf population.~To evaluate treatment satisfaction in the local Gulf population.